期刊
EMERGING INFECTIOUS DISEASES
卷 27, 期 7, 页码 1902-1908出版社
CENTERS DISEASE CONTROL & PREVENTION
DOI: 10.3201/eid2707.203230
关键词
-
资金
- US President's Malaria Initiative (PMI) through PARMA
- Advanced Molecular Detection Initiative at the CDC
- Bioinformatics Fellowship Program
- CDC
- CDC Foundation
- Developing Excellence in Leadership and Genetics Training for Malaria Elimination (DELGEME) in Sub-Saharan Africa program through the Developing Excellence in Leadership, Training and Science Africa Initiative (DELGEME) [107740/Z/15/Z]
- Wellcome Trust (DELGEME) [107740/Z/15/Z]
- government of the United Kingdom
- New Partnership for Africa's Development Planning and Coordinating Agency
The global spread of drug resistance to antimalarial treatments poses a serious public health risk. Through sequencing samples from therapeutic efficacy studies in Africa, mutations associated with partial artemisinin resistance were detected but no validated or candidate artemisinin-resistance mutations were found.
The spread of drug resistance to antimalarial treatments poses a serious public health risk globally. To combat this risk, molecular surveillance of drug resistance is imperative. We report the prevalence of mutations in the Plasmodium falciparum kelch 13 propeller domain associated with partial artemisinin resistance, which we determined by using Sanger sequencing samples from patients enrolled in therapeutic efficacy studies from 9 sub-Saharan countries during 2014-2018. Of the 2,865 samples successfully sequenced before treatment (day of enrollment) and on the day of treatment failure, 29 (1.0%) samples contained 11 unique nonsynonymous mutations and 83 (2.9%) samples contained 27 unique synonymous mutations. Two samples from Kenya contained the S522C mutation, which has been associated with delayed parasite clearance; however, no samples contained validated or candidate artemisinin-resistance mutations.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据